Effects of Kenponashi-Artichoke Compound Supplement on CCl4-induced Chronic Hepatic Injury to Rats

Wan-Li Chu*, Wen-Chuan Lin and Li-Chan Yang

Effects of Kenponashi-Artichoke Compound Supplement on CCl4-induced Chronic Hepatic Injury to Rats. During the past decade, increasing evidence has shown that sanghuangporus sanghuang can protect the liver from fibrosis due to its oxidation resistance. A study in 2002 showed that sanghuangporus sanghuang extract can restore catalase and SOD activity and restore the expression of aerobic respiration enzymes by reducing peroxidation products, so as to inhibit CCl4 -induced late-stage liver fibrosis.
It has been proved that sanghuangporus sanghuang polysaccharide can inhibit cytochrome P-450 isoenzymes in the liver.

Additionally, it has been reported that the retinoic acid derivative separated from sanghuangporus sanghuang reduces the early liver fibrosis induced by transforming growth factor-β through lowering the generation of active oxygen and inhibiting the expression of several proteins. The main active ingredient of fructus schisandrae is schisandrin B, which has multiple pharmacological activities, including antioxidant, anti-inflammation, anti-tumor, and liver protection.

Some studies have indicated that schisandrin B protects liver cells from liver injuries induced by CCl4 and paracetamol by inhibiting the bioactivation induced by CYP and regulating the nuclear factor-erythroid related factor antioxidant response element and antioxidant response element. Nuclear factor- erythroid related factor a transcription factor that stimulates ARE, can protect multiple tissues and cells from oxidation reactions.

Additionally, studies have indicated that schisandrin B inhibits the fibrosis signaling mediated by transforming growth factor-β  in vascular smooth muscle cells and alpha mouse liver cells. All of the above findings showed that schisandrin B can protect liver cells from injury and inhibit the activation of hepatic stellate cells induced by TGF-β, indicating that it could be used to treat liver fibrosis.

Liver Res Open J. 2023; 4(1):7-17. doi: 10.17140/LROJ-4-114